Clostridium difficile

Fecal microbiota transplantation (FMT) is a practice that many people may have not heard of, or possibly do not fully understand. FMT is a treatment that can help get rid of many different conditions such as Clostridium difficile infection (CDI) and other various diseases and infections. I have read the article Fecal Microbiota Transplantation and Emerging Applications by Thomas J. Borody and Alexander Khoruts and now have a better understanding of FMT and what it can do to help make advancements

assist with digestion, and prevent harmful bacteria from colonizing within the digestive tract (Boyle, Ruth-Sahd, & Zhou, 2015). Infections such as Clostridium difficile that disrupt this balance have a major impact on the gut microflora and have become increasing more difficult to treat due to the emergence of new strains of the bacteria. Clostridium difficile infection (CDI) is now seen as one the primary causes of hospital acquired infections in the southeast United States and is considered to be more

Article Analysis The health care profession has dramatically changed over years in an attempt to improve patients’ outcome. For this reason, nurses have to be aware of rising health care issues as well as evidence-based recommendations that can improve these problems. Rising health care issues that are being explored include the advantage of pharmacological treatment based on individuals’ genetic makeup, the rise of urinary tract infections (UTIs), as well as recommendations for preventing heart

the presence of Clostridium Difficile toxins in the stool. The toxins are used to diagnose antibiotic-associated diarrhoea and pseudomembranous colitis caused by C. diff (Labtestsonline.org.uk, 2016). Clostridium difficile is a gram positive; spore-forming rod and it is part of the flora neonates. It contains 3 types of toxins- Toxin A, Toxin B and binary toxins. Toxins A and B are proinflammatory and cytotoxic, they are the primary markers for the identification of C. difficile as they cause the

The study trial clearly focused on the effectiveness that S. boulardii had on the prevention of AAD and Clostridium difficile-associated diarrhea (CDAD) the use of the probiotics to prevent this. The population focus was hospitalized adults. A total of fifteen hospitals were included in the trial. Two thousand four hundred and forty-four patients were initially screen

C. difficile.6 C. difficile can also cause a build-up of dead mucosal cells, pus, and bacteria in the large intestine to create pseudomembranous colitis (PMC) covers the intestinal wall which affects the fluid reabsorption and contributes to the vast amount of diarrhea, and dehydration.3 In the last decade C. difficile infections have increased dramatically, one of the reasons could be

Introduction Clostridium difficile or more commonly known as C. diff is a bacterium that lives in the microflora of human intestines. Clostridium, refers to its spindle shape, and difficile is Latin for difficult. It gets its name because it is very hard to kill. This bacterium is able to in anaerobic conditions and it can live on a surface for up to 90 days. Each year C. diff infects roughly 500,000 people in the United States and often causes hospitalization (AGA). C. diff is able to infect a

Current Event: Microorganisms Causing C-diff Clostridum difficile is excess of bacterial growth which releases toxins that attach the lining of the intestines, which causes colitis. It is the bacterium in relationship to the bacteria that causes tetanus and botulism. The bacteria of Clostridum difficile can be found in numerous places, the most common places are in hospitals and health care facilities. The spores of the bacteria are mostly passes through feces and then passed on via food or other

The health care profession has dramatically changed over years in an attempt to improve patients’ outcome. For this reason, nurses have to be aware of rising health care issues as well as evidence-based recommendations that can improve these problems. Rising health care issues that are being explored include the advantage of pharmacological treatment based on individuals’ genetic makeup, the rise of urinary tract infections (UTIs), as well as recommendations for preventing heart disease in women

Chief Complaint/ History of Present Illness: Mindy Perkins is 48 year old woman who presents to the ED with 10- 15 loose, liquid stools daily for the past 2 days. She completed a course of oral Amoxicillin seven days ago for a dental infection. In addition to loose stools, she complains of lower abdominal pain that began 2 days ago as well. She has not noted any blood in the stool. She denies vomiting, fever, or chills. She is on Prednisone for Crohn’s disease as well as Pantoprazole (Protonix)